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Abstract: SOX genes are developmental regulators with functions in the instruction of cell fate and maintenance of 
progenitor’s identity during embryogenesis. They play additional roles during tissue homeostasis and regeneration 
in adults particularly in the Central Nervous System (CNS). In the last years a growing number of evidences has 
shown that mutations and dysfunction of SOX factors are implicated in several human diseases, including a variety 
of cancers. In this review, we will summarize the current knowledge about SOX family in CNS tumors and their role 
in the origin and maintenance of the subpopulation of cancer stem cells in these tumors.
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SOX family introduction
SOX (Sex-determining region Y (SRY)-box pro-
tein) family members are characterized by a 
conserved high mobility group (HMG) DNA-
binding domain [1]. There are, at least, 20 
members divided into 8 groups (from A to H), 
based on their HMG sequence identity in 
humans [2]. Members within a group preserve 
higher than 80% identity in their HMG-domain 
and share other well-conserved regions [3]. In 
addition, they share biochemical properties, 
have overlapping expression patterns and per-
form synergistic or redundant functions. In con-
trast, members from different groups usually 
perform different functions. SOX genes are 
developmental regulators with functions in sex 
determination, chondrogenesis, hematopoie-
sis, neural crest development and neurogene-
sis [4]. SOXB1, SOXB2, and SOXE members 
have a role in the instruction of cell fate and 
maintenance of progenitor’s identity during 
embryogenesis. They are also important for 
stem cell maintenance and play additional 
roles during tissue homeostasis and regenera-
tion in adults particularly in the CNS [5]. In the 
last years a growing number of evidences have 
shown that mutations and dysfunction of SOX 
factors are implicated in several human diseas-
es, including a variety of cancers [6]. These dis-
eases are originated in tissues overlapping with 
their expression pattern during embryonic 
development. Since SOX factors play an integral 
role in the maintenance of neural stem cells 
and in the specification and differentiation of 
neurons, astrocytes and oligodendrocytes, it 
seems reasonable to surmise that aberrant 
expression of members of this family is impli-
cated in the development and maintenance of 
CNS tumors. 
Central nervous system tumors
Tumors of the CNS consist of a heterogeneous 
group of neoplasias accounting for around 3% 
of the total number but representing 7% of 
deaths caused by cancer. Every year in the 
world, approximately 350.000 people are diag-
nosed with gliomas, making it the most com-
mon primary brain tumor (IARC http://globocan.
iarc.fr, accessed on day/month/year). Gliomas 
display histological similarities to glial cells and 
according to which cell they most resemble, the 
World Health Organization (WHO) classifies 
them into astrocytoma, oligodendroglioma, 
ependymoma or mixed oligoastrocytoma. This 
classification is based solely on morphology. 
Based on histopathological and clinical criteria 
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they are classified into four classes of malig-
nancy [7].
Glioblastoma multiforme (GBM) belongs to 
grade IV and accounts for 80% of the total pri-
mary malignant brain tumors in adults. The inci-
dence ranges from 5 to 20 cases per 100,000 
people per year [8] with an associated median 
survival of 15 months [9]. This survival identi-
fies GBM as one of the most aggressive and 
fatal cancer overall. 
The clinical hallmarks of GBM are its aggres-
sive growth and inexorable recurrence as a 
consequence of the resistance to apoptosis, 
genomic instability and poor response to thera-
py [10]. It is also characterized for the presence 
of necrotic areas, for being highly invasive, infil-
trative and with intense angiogenesis. In the 
last years different GBM characterizations have 
emerged based on the molecular knowledge of 
the genome [11-14] and transcriptome [15, 16]. 
These studies have provided a high-resolution 
picture of the GBM landscape uncovering the 
major structural genomic and expression alter-
ations that may drive disease pathogenesis 
and biology. These comprehensive data sets 
reveal GBM as a heterogeneous collection of 
distinct diseases with multiple dependencies 
both within and across each particular subtype. 
Contributing to this grim picture is the fact that 
despite a huge effort to understand this dis-
ease and to develop effective therapies over 
the past few decades, there are still no such 
agents [17]. 
CNS tumors constitute the largest group of 
solid neoplasms of childhood and the ones that 
cause the highest mortality rates in this group 
age [18]. Because the developing brain is highly 
vulnerable to treatment-induced cognitive and 
endocrine sequelae, particularly from radio-
therapy, ongoing studies are focusing on 
improving the duration and the quality of sur-
vival, in affected patients [18]. Medulloblastoma 
(MB) is the most common pediatric brain can-
cer and the treatment of patients with this dis-
ease poses an additional problem. Current 
therapies for MB cause dramatic impairment of 
cognitive function and predispose patients to 
future treatment-associated neoplasms [19]. 
Pediatric high-grade gliomas (pHGG) including 
diffuse intrinsic pontine glioma (DIPGs) com-
prise 15% to 20% of all childhood tumors of the 
CNS, and more than 70% of patients die within 
2 years of diagnosis. Consequently, under-
standing the molecular circuitries underlying 
the development of pHGG is crucial to identify 
relevant therapeutic targets [20] for these 
neoplasms. 
The cellular origin of CNS tumors
For many years, cancer has been based on a 
stochastic model, which considers that all cells 
within the tumor are highly proliferative, pos-
sess tumorigenic potential and are capable of 
tumor progression and repopulation. In the last 
decade, the demonstration that cancers are 
heterogeneous masses containing a hierarchy 
of cells has modified the original model [21]. 
This new theory postulates that a small sub-
population of cancer cells (called cancer stem 
cells, CSCs) drives tumor formation, growth, 
metastasis and resistance to therapeutic treat-
ments [22]. There is compelling evidence in 
support of its existence in hematological malig-
nancies and in numerous solid epithelial types 
of cancer including GBM and medulloblastoma 
[23]. In the brain, the CSCs population display 
Neural Stem Cells (NSCs) characteristics; 
unlimited proliferation, self-renewal potential 
and multipotency to differentiate into astro-
cytes, oligodendrocytes and neurons (Figure 
1). Furthermore, these cells form tumors phe-
notypically similar to the original human ones 
when injected into the brain of immunodeficient 
mice, indicative of being responsible for the ini-
tiation and maintenance of adult and pediatric 
brain tumors [24-26]. CSCs display much great-
er tumorigenic potential than matched non-
stem tumor cells, have the ability to migrate 
and are more resistant to apoptosis and thera-
py suggesting that these cells are also respon-
sible for tumor relapses particularly in GBM 
cases [27].
The demonstration of functional neurogenesis 
in the adult brain [28, 29], the observation of a 
population with stem cells properties within the 
tumor bulk, opened the debate regarding the 
putative cell of origin of CNS tumors and postu-
lated NSCs as the putative cell of origin for CNS 
tumors, mainly gliomas. Indeed, different 
genetic models have revealed that inactivation 
of p53/Rb/Pten/Nf1 tumor suppressors or 
enhancement in EGFR/PDGFR/PI3K oncogenic 
pathways in NSCs serve as glioma source [30, 
31]. Intriguingly, different studies have demon-
strated that targeting the same pathways in 
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Figure 1. Glioma cell of origin and glioma stem cell (GSC) evolution. Normal cellular hierarchy comprises neural 
stem cells that progressively produce new stem cells and more restricted progenitor cells, finally yielding oligoden-
drocytes, astrocytes and neurons. Accumulation of genetic mutations in different cell types is sufficient to induce 
gliomas. These gliomas contain a population of GSCs with self-renewal capacity and ability to differentiate to all the 
lineages.
astrocytes, oligodendrocyte progenitors and 
neurons is sufficient to undergo oncogenic 
transformation and form malignant gliomas 
[32-34]. These evidences strongly indicate that 
glioma cell of origin is diverse probably explain-
ing the complex and heterogeneous pathology, 
morphology and clinic that characterize this 
type of tumor (Figure 1). 
The concept of CSC may have profound implica-
tions from the point of view of therapy in that 
expose this population as a crucial target [35]. 
Therefore dysregulation of pathways controlling 
normal NSCs could constitute a requirement 
for cancer development and might play pre-
dominant roles in CSCs too. For example Notch 
is required from the transition from primitive to 
definitive NSC and their maintenance. 
Aberration in Notch pathway results in tumor 
formation and its expression is deregulated in 
GBM [36, 37]. Sonic Hedgehog (SHH) pathway 
is required for neural stem/progenitor cell 
maintenance promoting their proliferation and 
self-renewal [38] and this pathway is also found 
deregulated in GBM [39]. Furthermore, a recent 
elegant study has demonstrated how develop-
mental and regional differences influence neo-
plastic transformation in the CNS [40]. Thus, an 
active N-Myc mutant (T58A) generates medul-
loblastoma/primitive neuroectodermal tumors 
when transduced in cerebellar and brain stem 
NSCs, whereas develops diffuse glioma in fore-
brain NSCs. Tumors generated from diverse 
regions display different gene expression pat-
tern including SHH dependence and indepen-
dence within tumors from embryonic versus 
postnatal cerebellar NSCs [40]. Sox family 
members are critical transcription regulators of 
embryonic and neural stem cells, which are 
aberrantly expressed in several human cancers 
including GBMs. We plan to discuss, further 
down, their role in the development of the CNS 
and the implication of its deregulation in CNS 
tumors with particular attention in glioblasto-
ma (Figure 2).
SOX2
SOX2 is a member of the SOXB1 (together with 
SOX1 and SOX3) required for the maintenance 
of the early embryo, before implantation [41]. 
SOXB1 group members are coexpressed in the 
neuroepithelium and show certain degree of 
functional redundancy in the developing CNS 
[41]. In particular, SOX2 is one of the four 
essential factors required for induced pluripo-
SOX and central nervous system tumors
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Figure 2. Balance between 
SOX members in the regula-
tion of GSCs. Different SOX 
members display opposite 
functions in the regulation 
of GSCs. However, it remains 
elusive whether they are in-
volved in the initiation of the 
glioma.
tent stem (iPS) cell induction [42]. It is widely 
expressed in the embryo, in particular in the 
developing CNS where its expression is initiat-
ed concomitant with the acquisition of neural 
progenitor identity and it functions to maintain 
it [1, 43, 44]. In the adult, its expression is 
maintained in different populations of stem 
cells [45-48], acting intrinsically to confer stem 
cell properties, but also more broadly by regu-
lating the expression of critical niche factors as 
observed in the CNS [49]. 
SOX2 and GBM
SOX2 is highly expressed in several human can-
cers [50], including GBM [51-53]. Interestingly, 
the expression of SOX2 and other stem cell 
markers identifies a subset of patients with the 
poorest clinical outcome highlighting the clini-
cal relevance of SOX2 in GBM and in several 
other neoplasms [54].
Functionally, SOX2 is enriched in human-
derived glioma stem cells (GSCs) where it sus-
tains stemness properties and maintenance of 
tumorigenicity [55, 56]. Indeed, siRNA-mediat-
ed downregulation of SOX2 in GSCs impaired 
proliferation and their ability to form tumors in 
vivo [55]. SOX2 maintains GSC stemness using 
the same molecular targets of normal NSCs 
[55], supporting a hierarchical model of GBM 
controlled by SOX2 and opening the approach 
to find downstream genes as therapeutic tar-
gets. Furthermore, elevated expression of 
SOX2 is essential but not sufficient for main-
taining the self-renewal of GSCs [53] indicating 
that other factors cooperate to activate stem 
cell-like properties. Supporting this notion, just 
recently Suva et al identi-
fied a core set of neurode-
velopmental transcription 
factors (TFs) (POU3F2, SO- 
X2, SALL2, and OLIG2) ess- 
ential for GBM propagation. 
These TFs coordinately bind 
and activate stem-like tu- 
mor propagating cells (TP- 
Cs)-specific regulatory ele-
ments and are sufficient to 
fully reprogram differentiat-
ed GBM cells to “induced” 
TPCs, recapitulating the epi-
genetic landscape and phe-
notype of native TPCs [57]. 
In addition, SOX2 drives 
additional cancer-associated phenotypes and 
SOX2-driven malignant GSCs are highly inva-
sive and have migratory characteristics [53], 
mimicking those of NSCs [58]. Indeed, SOX2 
depletion induced attenuated cell proliferation 
is caused by decreased levels of Cyclin D1 [59], 
while the impaired invasive activity is mediated 
by inhibition of focal adhesion kinase (FAK) sig-
naling and downstream proteins such as HEF1/
NEDD9 and matrix metalloproteinases 1 and 2 
[59].
In the last years the mechanism of SOX2 acti-
vation in GBM has started to be unraveled. Our 
group identified SOX2 gene amplification and 
promoter DNA hypomethylation in a set of GBM 
patients as the leading mechanism responsible 
for SOX2 aberrant expression [53]. SOX2 pres-
ents a high CpG density throughout the promot-
er that may poise the gene for repression upon 
differentiation [60], suggesting that SOX2 pro-
moter hypomethylation in GBM might reflect a 
more primitive cellular state resembling that 
found in NSCs [60]. SOX2 is also regulated tran-
scriptionally and acts downstream relevant 
pathways in GBM formation. TGF-β regulates 
GSCs through SOX2 [56]. PDGF also modulates 
SOX2 activity. In fact, transforming activity of 
PDGF in neural progenitors and PDGF-
dependent tumors in mice triggered SOX2 
expression [61]. In human GSCs, siRNA-induced 
downregulation of SOX2 confers sensitivity to 
treatment with PDGF and IGF1 receptor inhibi-
tors [62] suggesting that resistance to PDGF 
and IGF1-receptor inhibitors in GBM are related 
to SOX2 expression. Moreover, SOX2 is activat-
ed at translational level by eukaryotic initiation 
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Figure 3. SOX2 functions in tissue homeostasis and cancer. 
SOX2 is emerging as a very complex factor with multiple func-
tions. Here we include the most relevant for glioma.
factor 4E (eIF4E) [63]. Indeed, there is a posi-
tive correlation between SOX2 and eIF4E in 
GBM human samples and down-regulation of 
eIF4E decreases SOX2 protein level without 
altering its mRNA level in GSCs. Post-trans- 
criptionally, different miRNAs including miR-9, 
miR-145, miR-21, miR-137 regulate GSCs and 
impart chemoresistance regulating SOX2 activ-
ity [64-67]. 
In order to address downstream targets of 
SOX2, microarray analyses identified 489 
genes and 105 precursor microRNAs whose 
expression is altered in response to SOX2 
silencing [68]. Among the relevant identified 
targets, BEX1 and BEX2 tumor suppressors 
and miR-143, miR-145, miR-253-5p and miR-
452 are downregulated with SOX2 knockdown. 
Interestingly, in this study they found that SOX2 
and miR-145 form a double negative feedback 
loop [68]. It is known that miR-145 acts to 
silence multiple pluripotency factors, including 
SOX2, [69] during the switch from self-renewal 
to lineage commitment. Therefore it might be a 
mechanism to regulate the balance between 
an undifferentiated and committed state. 
However, this regulation warrants further inves-
tigation to determine their putative function in 
GBM.  
In a very elegant study conducted by the group 
of Dr. Silvia Nicolis they address the question 
whether Sox2 was required by oligoden-
droglioma stem cells, mirroring its require-
ment for normal NSCs. They used their 
Sox2flox conditional mutation [70], in 
combination with the pHGG mouse model 
[61], to address the effects of Sox2 abla-
tion on tumor reinitiation following tumor 
cell transplantation into brain. As expect-
ed, mice transplanted with SOX2-deleted 
cells remained tumor-free throughout the 
time window in which controls developed 
lethal tumors. Moreover, they showed that 
loss of tumorigenesis of SOX2-ablated 
cells was prevented by transduction with a 
Sox2-expressing virus. From a more prac-
tical point of view they demonstrated that 
vaccination with Sox2 peptides elicited a 
response that significantly delayed tumor 
development, underscoring the feasibility 
of using SOX2 as a target [71]. 
Among the other SOXB1 members, the 
role of SOX1 and SOX3 in GBM has not yet 
been studied but the knockdown of SOX2 
inhibits the expression of SOX1 suggesting that 
this member might also display a role in this 
type of neoplasia [68]. Further studies will be 
necessary to clarify the role of SOX1 and SOX3 
in GBM.
Together, all these results underscore the 
major role that SOX2 displays in the malignant 
phenotype of GBM.
SOX2 and pediatric tumors
Pathways essential for promoting neural pre-
cursor proliferation or growth arrest and differ-
entiation have been implicated in CNS cancers 
and specifically in pediatric brain tumors; such 
as Sonic Hedgehog in medulloblastoma [72]. In 
agreement with this notion, Sox2 is upregulat-
ed in pHGG [75] and amplified in several pedi-
atric cell lines [76]. Moreover, high levels of 
SOX2 are detected in a tissue array of DIPGs, 
consistent with a role for tumor stem cells in 
the origin and maintenance of these tumors 
[77]. SOX2 is also expressed in SHH-associated 
medulloblastoma with preponderance in ado-
lescent and adult cases [78]. Deciphering the 
molecular circuitries controlled by Sox2 in pedi-
atric brain tumors could provide insights into 
these neoplasm development, biology and pos-
sible novel molecular targeted therapies.
SOX and central nervous system tumors
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SOXB2
SOXB2 group (comprised by SOX14 and SOX21) 
is closely related to SOXB1. However, SOXB2 
factors possess a repression instead of a 
C-terminal transactivation domain [79] and 
functionally Sox21 promotes neurogenesis by 
counteracting the activities of SOXB1 proteins 
in the developing CNS [80]. The decision of 
neural precursors to self-renew or to undergo 
neuronal differentiation therefore depends on 
the balance of SOXB1 and SOXB2 factors. 
Analogous to their opposite roles in develop-
ment and differentiation, forced expression of 
SOX21 inhibits SOX2 and induces apoptosis in 
human glioma cells [81]. Moreover, SOX21 
inhibits gliomas progression in vivo by forming 
complexes with SOX2 and stimulating aberrant 
differentiation [82]. These results imply that 
SOX21 acts as a tumor suppressor negatively 
regulating SOX2. They further demonstrate the 
relevance of the balance between SOXB1 and 
SOXB2 in tissue homeostasis and disease in 
the CNS. 
SOXC
SOXC proteins are implicated in the biology of 
different brain tumors [83, 84] with SOX4 and 
SOX11 exhibiting opposing activities in GBM. 
On one hand, SOX4 is upregulated in human 
samples, where it is associated with TGF-β 
[85], an important signaling pathway in GBM 
formation and progression [86]. Functionally, 
the activation of canonical and non-canonical 
TGF-β signaling enhances GSCs tumor activity 
through SOX4 protein and consequent boost of 
SOX2 [56]. Further supporting this axis, inhibi-
tion of TGF-β signaling drastically decreases 
the tumorigenicity of GSCs by promoting their 
differentiation, and these effects are restored 
by SOX2 or SOX4 re-activation [56]. SOX4 
Table 1. Major discoveries associated to SOX2 protein in CNS tumors
Sox member Finding Reference
SOX2-Glioblastoma sustains stemness properties and tumorigenicity [55]
Transcriptional regulation mediated by TGF-β [56]
Genetic and Epigenetic modifications [53]
Factor responsible for glioblastoma stem cells reprogramming [57]
SOX2-medulloblastoma Sustains stemness properties but not involved in tumor survival [78]
SOX2-oligodendroglioma Required to maintain stemness properties and tumorigenicity [71]
SOX4-Glioblastoma Sustains stemness regulated by TGF-β and modulating SOX2 [56]
induces the expression of SOX2 forming coop-
erative complexes with OCT-4 that bind to the 
SOX2 promoter [56]. In addition to their func-
tion regulating GSCs, combined high expres-
sion of OCT-4, SOX4 and SOX2 confers lower 
patient survival and correlates with p53-mutat-
ed status in GBM cases [87], highlighting the 
clinical relevance of this axis. Further investiga-
tions have revealed that SOX4 acts downstream 
of miR-204 to suppress GSCs self-renewal [88]. 
In summary, these findings indicate that SOX4 
is a master regulator of GSCs although it 
remains unresolved whether Sox4 positive cells 
are the cells of origin of GBM. They also high-
light that SOX transcription factors can act 
sequentially in tumor development, mimicking 
the action of those in neural lineage develop-
ment [80]. 
The role of SOX11 in GBM is less clear. On one 
hand, SOX11 is transcriptionally overexpressed 
in GBM [89]; however, low levels correlate with 
a significant decrease in patient survival [90]. 
Agreeing with this notion, GSCs have lost 
SOX11 expression, and its ectopic restoration 
prevents their tumorigenesis in vivo blocking 
the expression of oncogenic Plagl1 [90]. 
Moreover, the identification of an immunogenic 
CD8+ T cell epitope derived from SOX11, which 
is abundantly and specifically overexpressed in 
malignant glioma, emphasizes the suitability of 
this protein for a T cell-based immunotherapy 
for these patients [91].
SOXE
SOX9 belongs to the related SOXE family and its 
presence during embryonic development and 
in adulthood has been associated with stem 
cell maintenance in the pancreas, hair follicle, 
breast intestine and CNS [92, 93-95]. In the 
CNS, Sox9 is essential for gliogenesis and, in 
conjunction with Sox10, also maintains the 
SOX and central nervous system tumors
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multipotency of neural crest stem cells as well 
as directing differentiating cells to non-neuro-
nal fates [96]. It acts as a downstream effector 
of the Shh and Notch pathways [93, 97]. 
SOX9 expression levels are significantly higher 
in gliomas than in brain control tissue and 
increasing WHO grade gliomas display stronger 
SOX9 staining, together with higher SOX10 
[98]. From the clinical point of view, the 
increased expression of SOX9 in GBM signifi-
cantly correlates with a lower Karnofsky perfor-
mance score. In addition, patients with high 
SOX9 expression present lower disease-free 
and overall survival rates than those with low 
SOX9 [99]. Thus, SOX9 expression might be a 
relevant independent prognostic factor for 
GBM patients. Other brain tumors such as 
medulloblastomas and ependymomas also dis-
play robust SOX9 expression [84]. 
Functionally, SOX9 knockdown impairs cell pro-
liferation in glioma cell lines [100], induces the 
cell arrest in G2/M phase of cell cycle and 
enhances the apoptosis in glioma cells [99]. 
The inhibition of its activity mediates the 
impaired cell cycle progression and reduced 
cell invasion induced by miR-145 tumor sup-
pressor [101]. In contrast, ectopic expression 
of SOX9 cooperates to transform NSCs and 
form tumors with a primitive neuroectodermal 
tumor profile [40], establishing his functional 
relevance in the regulation of GSCs (Figure 1). 
Beyond the CNS tumors, Sox9 interacts with 
pathways and genes also altered in GBM such 
as EGFR, BMI-1 and PTEN [102-105] and these 
connections might be interesting to be further 
investigated in GBM.
Other SOX members might have a prominent 
role in GBM as well. SOX5 and SOX6 are highly 
expressed in glioma while are not detected in 
non-neoplastic tissues [106, 107]. Furthermore, 
there is a positive correlation between the 
presence of SOX5 and SOX6 IgGs from the sera 
of glioma patients and GBM patients survival 
suggesting they may be useful not only as diag-
nostic markers, but also as prognostic markers 
in glioma patients [107]. Finally, SOX17 expres-
sion in glioma endothelial cells is related to the 
angiogenic properties of tumor vessels, sug-
gesting that SOX17 might play a relevant func-
tion in GBM promoting tumor angiogenesis and 
vascular abnormalities [65].
In summary, SOX proteins are differently 
expressed in GBM with the majority of them 
inducing aberrant cell growth and promoting 
tumorigenic activities at various levels. 
However, their function needs to be further 
investigated in order to determine whether tar-
geting SOX proteins is a promising therapeutic 
strategy for GBM in humans.
Future perspectives
SOX factors are critical regulators during 
embryogenesis playing an integral role in the 
maintenance of NSCs and lineage differentia-
tion both during embryo development and adult 
stage. Furthermore, their aberrant expression 
is observed in malignant gliomas where they 
exhibit various features of tumorigenesis and 
tumor progression. SOX2, SOX4 and SOX9 have 
been consistently shown to act as oncogenes 
while SOX11 and SOX21 behave as tumor sup-
pressors (Figure 2). We have summarized the 
main role of the different SOX in CNS tumors in 
Table 1. Other members have not displayed a 
clear function yet. 
The outcome of SOX factors activation seems 
to depend on the tumor origin and cellular con-
text reflecting their roles in different territories 
during development. They regulate key pro-
cesses related to tumor biology, including cell 
proliferation, migration, epithelial mesenchy-
mal transition, angiogenesis, apoptosis, and 
regulation of GSCs and their opposite roles in 
these processes could be related to, yet unex-
plored, regulation of protein activity through 
transcriptional, post-transcriptional and post-
translational events. Future insight into the 
identification and functional characterization of 
their downstream target genes in GBM mainte-
nance and progression are needed to deter-
mine which SOX may be targeted as a thera-
peutic strategy for GBM.  
Among all the SOX factors, SOX2 is emerging as 
a very complex factor with multiple functions 
(Figure 3) not only in transcription but also in 
chromatin remodelling possibly through its 
association with the swi/snf complex, NuRD 
complex and others [108]. Moreover, it has 
been suggested a role of SOX2 in post-tran-
scription regulation through its association with 
RNA binding proteins [109] and a putative role 
as a RNA splicer [110]. These functions have 
been previously ascribed to central regulator 
SOX and central nervous system tumors
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such as p53 [111]. Nevertheless, further exper-
iments will be necessary to clarify the function-
al role and the mechanisms of these interac-
tions to understand the complexity of SOX2 
networks. This information might indicate that 
Sox2 targeting should be considered in ongoing 
efforts to develop novel stem cell targeting 
therapies. We have ahead of us a very interest-
ing horizon that comes with sophisticated tools 
such as RNA deep sequencing, ChIRP, RIP-seq, 
among others, that will allow us to study and 
decipher the secrets that SOX family members 
are still hiding. Understanding the underpin-
nings of these molecular networks would allow 
proposing tailored therapies against SOX 
deregulation.
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